VERTEX PHARMACEUTICALS INC / MA Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $119.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $119.50M, a 0.25% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $119.20M, a 2.76% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $116.00M, a 9.59% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $128.30M, a 205.48% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month as first filed |
|---|---|---|
| 2025-12-31 | $119.50M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $119.20M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $116.00M 10-K · filed 2026-02-13 | |
| 2022-12-31 | $128.30M 10-K · filed 2025-02-13 | |
| 2021-12-31 | $42.00M 10-K · filed 2024-02-15 | |
| 2020-12-31 | $26.70M 10-K · filed 2023-02-10 | $26.65M 10-K · filed 2021-02-11 |
| 2019-12-31 | $14.50M 10-K · filed 2022-02-09 | $14.41M 10-K · filed 2020-02-13 |
| 2018-12-31 | $9.70M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $3.81M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $0.00 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |